Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
FR0012333284
Wed, 23.08.2023
ABIVAX
Abivax appoints Patrick Malloy as Senior Vice President Investor Relations
PARIS, France, August 23, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”) today announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations. Mr. Malloy brings 20 years of investor relatio [ … ]
Mon, 21.08.2023
ABIVAX
Abivax secures up to EUR 150M from two structured debt financing transactions
Up to EUR 75M from Kreos Capital and Claret European Growth Capital
Up to EUR 75M from Heights Capital Management
EUR 27M of additional cash resources for Abivax at drawdown of the first tranches
PARIS, France, August 21, 2023, 8:00 a.m. CEST – Abivax SA (Euronext Par [ … ]
Thu, 10.08.2023
ABIVAX
Abivax announces plans to conduct registered public offering in the United States
PARIS, France, August 10, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject [ … ]
Tue, 11.07.2023
ABIVAX
Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
PARIS, France, July 11, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic [ … ]
Tue, 11.07.2023
ABIVAX
Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
PARIS, France, July 11, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic [ … ]
Thu, 15.06.2023
ABIVAX
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
The award recognizes a significant capital market transaction in the biotech sector
Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023
P [ … ]
Thu, 15.06.2023
ABIVAX
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
The award recognizes a significant capital market transaction in the biotech sector
Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023
P [ … ]
Thu, 08.06.2023
ABIVAX
Abivax stock included in MSCI Indexes
As of June 1st, the Abivax stock is represented in the MSCI Indexes
The MSCI Indexes reflect the evolution of the world’s equity markets to support investors building effective portfolios based on risk and return assessments
PARIS, France, June 8, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 [ … ]
Thu, 08.06.2023
ABIVAX
Abivax stock included in MSCI Indexes
As of June 1st, the Abivax stock is represented in the MSCI Indexes
The MSCI Indexes reflect the evolution of the world’s equity markets to support investors building effective portfolios based on risk and return assessments
PARIS, France, June 8, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 [ … ]
Thu, 08.06.2023
ABIVAX
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
Shareholders approved all proposed resolutions
PARIS, France, June 6, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune syst [ … ]